Patent: 9,458,168

Summary for Patent: 9,458,168

Title:	Bicyclic-fused heteroaryl or aryl compounds
Abstract:	Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, ##STR00001## as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
Inventor(s):	Trzupek; John David (Medford, MA), Lee; Katherine Lin (West Newton, MA), Bunnage; Mark Edward (Concord, MA), Han; Seungil (Mystic, CT), Hepworth; David (Concord, MA), Lovering; Frank Eldridge (Acton, MA), Mathias; John Paul (Concord, MA), Papaioannou; Nikolaos (Boston, MA), Strohbach; Joseph Walter (Wentzville, MO), Wright; Stephen Wayne (Old Lyme, CT), Zapf; Christoph Wolfgang (Marlborough, MA), Gavrin; Lori Krim (Villanova, PA), Lee; Arthur (Gaithersburg, MD), Curran; Kevin Joseph (Somerset, NJ), Dehnhardt; Christoph Martin (Burnaby, CA), Saiah; Eddine (Brookline, MA), Goldberg; Joel Adam (New Orleans, LA), Wang; Xiaolun (San Diego, CA), Vargas; Richard (Bedford, MA), Lowe; Michael Dennis (White Plains, NY), Patny; Akshay (Waltham, MA)
Assignee:	Pfizer Inc. (New York, NY)
Application Number:	14/678,114
Patent Claims:	see list of patent claims

Details for Patent 9,458,168

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Janssen Biotech, Inc.	REMICADE	infliximab	For Injection	103772	08/24/1998		2039-02-26
Immunex Corporation	ENBREL	etanercept	For Injection	103795	11/02/1998		2039-02-26
Immunex Corporation	ENBREL	etanercept	For Injection	103795	05/27/1999		2039-02-26
Immunex Corporation	ENBREL	etanercept	Injection	103795	09/27/2004		2039-02-26